A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D

详细信息    查看全文

• 作者：David M Hyman ; MD^a ; ^{hymand@mskcc.org} ; Michael W Sill ; PhD^b ; ^{msill@gogstats.org} ; Heather A Lankes ; PhD^b ; ^{hlankes@gogstats.org} ; Richard Piekarz ; MD ; PhD^c ; ^{rpiekarz@nih.gov} ; Mark S Shahin ; MD^d ; ^{mshahin@abingtonhealth.org} ; Mildred R Ridgway ; MD^e ; ^{mridgway@umc.edu} ; Floor Backes ; MD^f ; ^{Floor.Backes@osumc.edu} ; Meaghen E Tenney ; MD^g ; ^{mtenney@bsd.uchicago.edu} ; Cara A. Mathews ; MD^h ; ^{cmathews@wihri.org} ; James S Hoffman ; MDⁱ ; ¹ ; ^{James.HoffmanMD@baystatehealth.org} ; Carol Aghajanian ; MD ; PhD^a ; ^j ; ^{aghajanc@mskcc.org} ; Martee L Hensley ; MD^a ; ^j ; ^{hensleym@mskcc.org}
• 关键词：Alisertib ; Aurora kinase ; Uterine leiomyosarcoma
• 刊名：Gynecologic Oncology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：144
• 期：1
• 页码：96-100
• 全文大小：358 K
• 卷排序：144

文摘

Uterine leiomyosarcomas are poor prognosis tumors with few effective treatments. Aurora-A kinase deregulations are common in uterine leiomyosarcoma. Alisertib monotherapy was not active in advanced/recurrent uterine leiomyosarcoma.